The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development

Abstract excerpt

In mid November the biopharma industry was shocked by the announcement from Geron that they were ending work on embryonic stem cell research and therapy. For more than 10 years the public image of all stem cell research has been equated with embryonic stem cells. Unfortunately, a fundamentally important medical and financial fact was being ignored: embryonic stem cell therapy is extremely immature. In parallel to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomedical Ethics and Regulation